2015-000417-44: A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with cancer of the eye that has spread to the liver. |
|
|
| Ongoing | 3 | 240 | Europe | Melphalan, Powder and solvent for solution for infusion, Melphalan Hydrochloride for Injection | Delcath Systems, Inc, Delcath Systems, Ltd, DELCATH SYSTEMS, INCORPORATIONS, Delcath Systems, Inc | Hepatic-Dominant Ocular Melanoma, Cancer of the eye that has spread to the liver, Diseases [C] - Cancer [C04] | | | | |
NCT05022901: An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma |
|
|
| Active, not recruiting | 3 | 30 | US | Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS), percutaneous hepatic perfusion, PHP, HEPZATO | Delcath Systems Inc. | Metastatic Ocular Melanoma, Metastatic Uveal Melanoma | 03/24 | 03/24 | | |
| Active, not recruiting | 2/3 | 295 | US | Melphalan/HDS, Melphalan/PHP, Cisplatin and Gemcitabine, Cis/Gem | Delcath Systems Inc. | Bile Duct Cancer, Intrahepatic Cholangiocarcinoma | 01/23 | 05/23 | | |